TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03967990

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50/50 refined cornmeal-bran mix
Description: 48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50/50 refined cornmeal-bran mix
Description: 48 g/d of a mix of 50% refined cornmeal flour and 50% corn bran flour served to participants as two daily 24 g servings via pita breads and/or muffins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain cornmeal flour
Description: 48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain cornmeal flour
Description: 48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain cornmeal flour
Description: 48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain cornmeal flour
Description: 48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain cornmeal flour
Description: 48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain cornmeal flour
Description: 48 g/d of whole grain cornmeal flour served to participants as two daily 24 g servings via pita breads and/or muffins
Study: NCT02870504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corneoscleral limbus group
Description: Laser spot locates on the corneoscleral limbus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: one spot group
Description: Laser spot locates on one spot away from the corneoscleral limbus

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two spots group
Description: Laser spot locates on two spots away from the corneoscleral limbus
Study: NCT00840372

Intervention type: PROCEDURE
Intervention: Buttonhole cannulation with semi-blunt needles
Description: Use of semi-blunt needles, compared to blunt needles, at every dialysis session

Intervention type: PROCEDURE
Intervention: Buttonhole cannulation with semi-blunt needles
Description: Use of semi-blunt needles, compared to blunt needles, at every dialysis session
Study: NCT00209222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: chemotherapy
Study: NCT00611117

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Level
Description: High vs. low physical activity during a high fat diet consumption.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Activity Level
Description: High vs. low physical activity during a high fat diet consumption.
Study: NCT02783118

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self administered online CBT
Description: The app being tested has two main components: courses and exercises. Courses represent the psycho-educational and therapeutic background of the program, comprising the following topics: information on depression, psychological vulnerability, what is CBT, healthy and unhealthy negative emotions, rational and irrational thoughts, how behaviors contribute to depression, sleep hygiene, social support, and relaxation techniques. Exercises use the information presented in the courses and follow the structure of a regular therapy session and/or therapeutic homework.~The following exercises are included in the app:~1. The Emotional Pulse exercise~2. The Sticky Notes exercise~3. The Find Irrational Thoughts~4. The Change Irrational Thoughts

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self administered online CBT
Description: The app being tested has two main components: courses and exercises. Courses represent the psycho-educational and therapeutic background of the program, comprising the following topics: information on depression, psychological vulnerability, what is CBT, healthy and unhealthy negative emotions, rational and irrational thoughts, how behaviors contribute to depression, sleep hygiene, social support, and relaxation techniques. Exercises use the information presented in the courses and follow the structure of a regular therapy session and/or therapeutic homework.~The following exercises are included in the app:~1. The Emotional Pulse exercise~2. The Sticky Notes exercise~3. The Find Irrational Thoughts~4. The Change Irrational Thoughts
Study: NCT03257293

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Cystoscopy
Description: The objective of this study is to examine whether a non-pharmacologic modification in procedure of cystoscopies improves patient perception of pain and discomfort.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Routine Cystoscopy
Description: Routine cystoscopy as done as part of routine clinical practice
Study: NCT03122756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Intravenous injection of dexamethasone 0.1 mg/kg maximum 8 mg (diluted with distilled water to 2 mL) just prior to administration of spinal anesthesia.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Intravenous injection 2 mL intravenous normal saline (0.9 %) just prior to administration of spinal anesthesia.
Study: NCT00209222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: corticosteroide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: corticosteroide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatinum
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara-C
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: corticosteroide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BCNU
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: chemotherapy
Study: NCT06617845

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation Set A and B
Description: Subjects will receive one stimulation parameter set first for 3 months and then the other for three months. Sets will include Set A (145 Hz high frequency stimulation) and Set B (Low frequency stimulation less than 40 Hz, which is similar to stimulation frequencies used during cortical stimulation). The 145 Hz stimulation will be set to cycling (1 min on, 5 min off) while the low frequency setting will be continuous. Both sets include stimulation parameter sets that have been used in clinical practice as a part of standard of care. However, it is unclear which set is better or whether they are similarly effective.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation Set A and B
Description: Subjects will receive one stimulation parameter set first for 3 months and then the other for three months. Sets will include Set A (145 Hz high frequency stimulation) and Set B (Low frequency stimulation less than 40 Hz, which is similar to stimulation frequencies used during cortical stimulation). The 145 Hz stimulation will be set to cycling (1 min on, 5 min off) while the low frequency setting will be continuous. Both sets include stimulation parameter sets that have been used in clinical practice as a part of standard of care. However, it is unclear which set is better or whether they are similarly effective.
Study: NCT06623539

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemafibrate high dose
Description: Pemafibrate 0.1 mg tablets shall be administered orally twice daily, two tablets per dose, after the morning and evening meals. If unavoidable, pemafibrate extended-release 0.2 mg for 2 tablets 1 or 0.4 mg for 1 tablet 1 can be substituted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemafibrate low dose
Description: Pemafibrate 0.1 mg tablets shall be administered orally twice daily, one tablet per dose, after the morning and evening meals. If unavoidable, pemafibrate extended-release 0.2 mg for 1 tablets 1 can be substituted.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate 53.3 mg tablets shall be administered orally once daily, one tablet per dose, after breakfast. Thereafter, the dose may be carefully increased to two tablets per dose at the physician\&amp;#39;s discretion.
Study: NCT01381835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 7 days
Study: NCT02299258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard stents MTN-CG-s-20/100
Description: The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tailored stents MTN-WE-20/100-A
Description: cup-shaped or funnel-shaped, according to the shapes of the proximal GOOs.
Study: NCT00485056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 45mgs daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone
Description: 45mgs daily
Study: NCT04229680

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Salt
Description: Consumption of pills containing table salt for 10 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Recommended Salt
Description: Consumption of pills containing dextrose for 10 days.
Study: NCT04213313

Intervention type: DRUG
Intervention: Treatment of bacterial keratitis
Description: 0.3% Levofloxacin Eye Drops or 0.3% Tobramycin Eye Drops QID

Intervention type: DRUG
Intervention: Treatment of fungal keratitis
Description: 1% Fluconazole Eye Drops or 0.25% Amphotericin B Eye Drops QID

Intervention type: DRUG
Intervention: Treatment of viral keratitis
Description: 0.1% Acyclovir eye drops QID ，Ganciclovir gel QN，Famiclovir tablets 0.25g TID

Intervention type: DIAGNOSTIC_TEST
Intervention: corneal scraping
Description: culture and sensitivity of corneal ulcerated infiltrating edge tissue

Intervention type: OTHER
Intervention: Sequencing
Description: polymerase chain reaction with sequence specific primers(PCR-SSP) and Sanger sequencing

Intervention type: OTHER
Intervention: Sequencing
Description: polymerase chain reaction with sequence specific primers(PCR-SSP) and Sanger sequencing
Study: NCT04639089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platlet rich plasma on sternal healing post median sternotomy
Description: Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA~Intraoperative :~We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.~post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: platlet rich plasma on sternal healing post median sternotomy
Description: Patient data will be collected preoperatively and intraoperatively and these risk factors will be studied Patients will be distributed to two equal groups. Demographic data : Age - gender - weight - BMI-DM-hist. of radiotherapy exposure -BIMA~Intraoperative :~We will apply 10cm plasma contain 1 million platlets on the sternal edge of only one group of them before sternal closure.~post-operative The patients will be followed till being discharged from hospital and after the first 3 months after surgery
Study: NCT04181424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education Plus Monthly Food Vouchers
Description: Individuals assigned to this group will receive diabetes education and skills training and monthly food vouchers for use at local Farmer's markets mailed to their home.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education Plus Combination of Monthly Food Vouchers and Stock Boxes
Description: Individuals assigned to this group will receive diabetes education and skills training, monthly food vouchers for use at local Farmer's markets mailed to their home, and monthly stock boxes with diabetes appropriate food items mailed to their home.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education Only
Description: Individuals assigned to this group will receive diabetes education and skills training but will not receive food supplementation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education Plus Monthly Stock Boxes
Description: Individuals assigned to this group will receive diabetes education and skills training and monthly stock boxes with diabetes appropriate food items mailed to their home.
Study: NCT01738893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Description: Test product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Description: Reference product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg
Description: Reference product
Study: NCT02439177

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system (Omnitest 3)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood glucose monitoring system (Omnitest 5)
Study: NCT02381002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight reduction program
Description: Overweight and obese children (6-12 years old) from patient group accepting enrollment were assigned to weight reduction program for 6 months with monthly follow up. The program comprise: 1) Diet regimen: Healthy balanced diet was prescribed. The amount of calories was determined according to 24-hour recall then 250-500 calories were subtracted from total intake which decrease weight by 0.25-0.5 kg/week. 2) Exercise:were instructed to practice walking for at least 30 minutes 3-4 times per week.
Study: NCT02314741

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POEM Procedure
Description: The procedure is performed under anesthesia.The procedure involves endoscopic electrosurgical dissection with an Olympus triangular tip knife.The myotomy is usually \~6cm long \& averages 8-10cm. After the myotomy is performed the scope is withdrawn \& inserted into the lumen to inspect the mucosa, ensure mucosal integrity \& confirm easy passage of the endoscope through the LES consistent with an adequate myotomy. The mucosal entry site is usually 2-3cm long, \& is closed with 5-10 endoscopic clips. Patients are hospitalized after procedure for observation.The patient is given IV-nutrition until post-operative day 1. An esophagram is obtained. If no loss of mucosal integrity or leak is noted, a liquid diet is started, which is continued for several days before initiating a solid diet.
Study: NCT06012565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAND567
Description: 2 x 125 mg capsules for oral administration. KAND567 (250 mg) was to be given every 12 hours for one week (7 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microcrystalline cellulose
Description: Capsules for oral administration, consisting of microcrystalline cellulose oral solid formulation in capsules. Placebo was to be given every 12 hours for one week (7 days).
Study: NCT03917810

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Macronutrient composition (specifically type and/or amount of carbohydrate) is manipulated
Study: NCT03748238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endometrial Injury with Hysteroscopy
Description: All office hysteroscopy procedures will be done transvaginally under sedation with a 5 mm 30 degree lens supplied with a 5 F working channel continuous flow office hysteroscope (Bettocchi office hysteroscope, Karl Storz, Tuttlingen, Germany) without speculum or tenaculum. Briefly, following cervical passage and initial endometrial cavity investigation endometrial injury will be performed without energy modality (i.e. with scissors). Endometrial injury will perform first on the fundus by cutting into the endometrium (without injuring the myometrium) transversally. Later, vertical incisions will perform 0,5 cm apart each other, on the anterior and posterior walls of the uterus, 1-1.5 cm away from the fundus and one cut for each lateral wall
Study: NCT01416701

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D (D3, cholecalciferol)
Description: Week 0-4: 152 mcg/daily (4 tablets) Week 5-52: 76 mcg/daily (2 tablets)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (cellulose)
Description: Week 0-4: 4 tablets daily Week 4-52: 2 tablets daily
Study: NCT00979602

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340274A
Description: One intramuscular injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2340273A
Description: One intramuscular injection
Study: NCT03767634

Intervention type: OTHER
Intervention: Parenteral nutrition
Description: Parenteral nutrition is the administration of an intravenous solution containing amino acids (with or without lipids) to provide nutritional support.
Study: NCT01782040

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auriculotherapy group
Description: It was used semipermanent needles (1.5mm) to stimulate points, once on a week, during 8 sessions.
Study: NCT00936221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD6244
Description: oral capsules, 75mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine
Description: 1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dacarbazine
Description: 1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03034213

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gentrix™ Surgical Matrix (Treatment)
Description: Gentrix™ Surgical Matrix will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend (Control)
Description: A biological or prosthetic mesh (Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend) will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
Study: NCT02921373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 19F Cell Sense-labeled PBMC
Description: Peripheral blood mononuclear cells (PBMC) will be isolated from patient whole blood samples and labeled in a GMP facility with GMP grade 19F Cell Sense imaging agent.~These cells will be re-administered to the patient prior to imaging.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 19F Cell Sense-labeled PBMC
Description: Peripheral blood mononuclear cells (PBMC) will be isolated from patient whole blood samples and labeled in a GMP facility with GMP grade 19F Cell Sense imaging agent.~These cells will be re-administered to the patient prior to imaging.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants will undergo Magnetic Resonance Imaging (MRI) at 1 hour and 24 hours following PBMC administration

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Participants will undergo Magnetic Resonance Imaging (MRI) at 1 hour and 24 hours following PBMC administration
Study: NCT03954457

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-CWS
Description: The A-CWS intervention is a 15-session culturally-grounded, cognitive-behavioral group intervention designed to develop and enhance African American youths' skills for coping with stress. The intervention structure allows implementation within traditional school and other community settings. The A-CWS uses standard cognitive-behavioral strategies (e.g., relaxation training, cognitive restructuring) to help African American youth identify and cope with individual and contextual stressors, using culturally consistent coping strategies. The intervention emphasizes the identification and management of stressors associated with suicide risk (e.g., racism-related stress, community violence exposure) and the unique experiences of low-resourced, urban African American adolescents (e.g., community violence exposure). The structured, manualized A-CWS curriculum is designed to be sustainable and user-friendly, to ensure that the A-CWS is delivered effectively and with a high degree of fidelity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Control
Description: The standard care control condition consisted of standard case management services delivered by the SBHC. Participants randomly assigned to the standard care control condition were referred to the SBHC social worker for case management. Standard care ranged from brief intervention by the SBHC social worker, to more intensive intervention by the SBHC social worker, to outside referral to local community service providers. SBHC social workers determined type and duration of services based on individual participant needs.
Study: NCT00758160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OROS Methylphenidate
Description: Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.